Can Fite BiopharmaCANF -1.97%55 Piotroski F-Score is 2 as of Jun. 25, 2026, which is at its 10-year median of 2.00. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,342 Biotechnology companies, Can Fite Biopharma ranks worse than 73.25% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Can Fite Biopharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Can Fite Biopharma's Piotroski F-Score or its related term are showing as below:
CANF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 2 Max: 3
Current: 2
During the past 13 years, the highest Piotroski F-Score of Can Fite Biopharma was 3. The lowest was 1. And the median was 2.
Can Fite Biopharma (AMEX:CANF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Can Fite Biopharma Piotroski F-Score Related Terms
Can Fite Biopharma Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Can Fite Biopharma's current Net Income (TTM) was -9.83.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Can Fite Biopharma's return on assets of this year was -1.07763158. Can Fite Biopharma's return on assets of last year was -0.78886775.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Can Fite Biopharma's gearing of this year was 0.00160996. Can Fite Biopharma's gearing of last year was 0.0053378.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Can Fite Biopharma's current ratio of this year was 3.4566093. Can Fite Biopharma's current ratio of last year was 4.37719298.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Can Fite Biopharma's number of shares in issue this year was 0.915. Can Fite Biopharma's number of shares in issue last year was 0.403.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Can Fite Biopharma's gross margin of this year was 1. Can Fite Biopharma's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Can Fite Biopharma's asset turnover of this year was 0.04440789. Can Fite Biopharma's asset turnover of last year was 0.06747422.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Can Fite Biopharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Can Fite Biopharma (CANF) has a Piotroski F-Score of 2 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Can Fite Biopharma and its competitors. This is near median its historical median of 2.00. Over the past decade, Can Fite Biopharma's Piotroski F-Score has ranged from 1.00 to 3.00. According to the industry distribution chart, Can Fite Biopharma ranks #983 out of 1342 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Can Fite Biopharma's Piotroski F-Score too high?
Can Fite Biopharma's current Piotroski F-Score of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 3.00. The Biotechnology industry median Piotroski F-Score is 3.00. Can Fite Biopharma's value of 2 is 33.3% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #983 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #983 out of 1342 companies for Piotroski F-Score. This places Can Fite Biopharma in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Can Fite Biopharma's value of 2 is 33.3% below this benchmark. Historically, Can Fite Biopharma's own Piotroski F-Score has ranged from 1.00 to 3.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 3.00, Can Fite Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Piotroski F-Score is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current Piotroski F-Score is 2, which is near median its 10-year median of 2.00 and 33.3% below the Biotechnology industry median of 3.00. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Piotroski F-Score is 2 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Piotroski F-Score: 2 (near median its 10-year median of 2.00)
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
Industry Position: 33.3% below the Biotechnology median (#983 of 1342)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
